NeuAc

NeuAc

Abbreviation for N-acetylneuraminic acid.
Mentioned in ?
References in periodicals archive ?
Katrina Metzler, executive director of the NEUAC, said LIHEAP was funded at S3 billion in fiscal 2017, the current fiscal year.
Katrina Metzler, executive director of the NEUAC, says the LIHEAP was funded at $3 billion in fiscal 2017, the current fiscal year.
NEUAC chairman John Rich said the funding would build upon President Obama's LIHEAP budget request.
NEUAC is national, broad-based and diverse organization that heightens awareness of the energy needs of low- and moderate-income Americans.
pneumoniae excrete neuraminidase, which catalyzes the hydrolysis of NeuAc residues from glycoproteins, explaining the apoC-III hyposialylation profile.
6] Nonstandard abbreviafions: CDG, congenital disorders of glycosylation; TIEF, transferrin isoelectric focusing; ApoC-III, apolipoprotein C-III; IEF, isoelectric focusing; Ga1NAc, N-acetylgalactosamine; NeuAc, sialic acid; FTC, familial tumoral calcinosis (MIM 211900); HIBM, hereditary inclusion body myopathy (MIM 600737); MEB, muscle-eye-brain disease (MIM 253280); HUS, hemolyfic uremic syndrome; HGPS, Hutchinson Gilford progeria syndrome (MIM 176670), F5FSD, a combined deficiency of factor V and factor VIII (MIM 227300); ER, endoplasmic reficulum; COG7, conserved oligomeric Golgi complex; CMP-NeuAc: cytidine 5'monophospho-N-acetylneuraminic acid; GNE/MNK, uridine-5'-diphosphate-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase; GALNT3, UDP-Ga1NAc transferase 3.
In addition to the 7 core structures, the Tn (GalNAc[alpha]1-Ser/Thr) and sialyl Tn [NeuAc[alpha]2-6GalNAc[alpha]1-Ser/ Thr; where NeuAc is N-acetylneuraminic acid (sialic acid)] epitopes can be distinguished.
Increased amounts of CMP-NeuAc were detected, whereas total amounts of serum NeuAc were decreased.
They differ in the number of NeuAc residues attached to the O-glycan core.
Gal and N-acetylneuraminic acid (NeuAc) are the only sugars implicated in the biosynthesis of both N-glycans and core 1 mucin type O-glycans; therefore, it is very likely that the genetic defect in patient B is situated in one of the three biosynthetic stages of one Gal or NeuAc.
In addition, it may implicate the transferases that transfer Gal or NeuAc to the N-glycan because these enzymes are thought to be N-glycan specific.
The purified compounds from a patient with [alpha]-NAGA deficiency (4), kindly provided by Dr Hirabayashi (Riken, Tsukuba, Japan), were NeuAc[alpha]2-3Gal[beta]1-3[NeuAc[alpha]26]Ga1NAc[alpha]1-Ser/Thr, where NeuAc is acetylneuraminic acid and Ga1NAc is N-acetylgalactosamine.